Aviragen Therapeutics Inc Share Price Nasdaq
Stocks
US0906941002
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| Market Cap | 119M 105M 97.56M 89.52M 168M 11.5B 171M 1.16B 453M 5.65B 448M 439M 19.55B | P/E 2026 * |
-2.54x | P/E 2027 * | -0.5x |
|---|---|---|---|---|---|
| Enterprise Value | 119M 105M 97.56M 89.52M 168M 11.5B 171M 1.16B 453M 5.65B 448M 439M 19.55B | EV / Sales 2026 * |
0.6x | EV / Sales 2027 * | 50.8x |
| Free-Float |
98.3% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Aviragen Therapeutics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Steven Lo
CEO | Chief Executive Officer | 60 | 17/03/2024 |
Sean Tucker
CTO | Chief Tech/Sci/R&D Officer | 59 | 29/02/2024 |
Jeroen Grasman
DFI | Director of Finance/CFO | - | 18/05/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
David Wheadon
BRD | Director/Board Member | 68 | 20/04/2021 |
William Watson
BRD | Director/Board Member | 76 | 03/08/2022 |
Elaine Heron
BRD | Director/Board Member | 79 | 31/12/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.93% | +6.97% | +59.60% | +68.35% | 57.28B | |
| -1.92% | +6.03% | +40.64% | +83.42% | 54.99B | |
| -0.46% | -1.29% | +2.86% | +428.78% | 23.18B | |
| -2.97% | -2.35% | -22.53% | -16.40% | 22.59B | |
| -0.36% | +5.73% | +24.13% | -6.24% | 20.46B | |
| -1.34% | +0.51% | +26.03% | -29.41% | 17.56B | |
| -1.44% | +5.67% | +38.77% | +504.71% | 15.67B | |
| -1.30% | -5.02% | +170.77% | +291.37% | 14.46B | |
| -0.50% | -0.98% | +21.43% | +180.07% | 13.92B | |
| Average | -1.04% | +1.28% | +40.19% | +167.18% | 26.68B | |
| Weighted average by Cap. | -0.87% | +2.10% | +39.70% | +133.49% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 200M 176M 164M 150M 282M 19.3B 287M 1.94B 760M 9.49B 752M 736M 32.81B | 2.35M 2.06M 1.92M 1.76M 3.31M 226M 3.36M 22.79M 8.91M 111M 8.82M 8.63M 385M |
| Net income | -24.4M -21.43M -19.93M -18.29M -34.37M -2.35B -34.9M -237M -92.48M -1.16B -91.62M -89.64M -4B | -266M -234M -217M -200M -375M -25.63B -381M -2.58B -1.01B -12.6B -999M -978M -43.57B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
